BIAL
Gold Partner
Information
BIAL is an innovative international pharmaceutical company with products available in more than 50 countries. Founded in 1924, BIAL's mission is to discover, develop and provide therapeutic solutions within the area of human health. In recent decades, the company has strategically focused on quality, innovation and internationalisation. BIAL consistently channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2009, BIAL launched eslicarbazepine acetate in Europe and later launched in the USA in 2014 in partnership with Sunovion. The drug was co-marketed in Europe with Eisai until February 2021.
At the end of 2016, BIAL launched and commercialised opicapone in Europe.
In September 2021, BIAL received exclusive rights from Sunovion to commercialise apomorphine sublingual film in Europe.
The BIAL headquarters are in Portugal, having extended its presence worldwide. The company has affiliates in three different continents - Europe, America and Africa - and its products are present in fifty countries, fulfilling its purpose of making a real difference in the lives of people living with severe diseases across the world.
Date of preparation May 2023
UK/BIAL/2023/025
